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Abstract 
Background and Objective: In silico prediction of drug-target interactions (DTI) could 
provide valuable information and speed-up the process of drug repositioning – finding 
novel usage for existing drugs. In our work, we focus on machine learning algorithms sup-
porting drug-centric repositioning approach, which aims to find novel usage for existing or 
abandoned drugs. We aim at proposing a per-drug ranking-based method, which reflects 
the needs of drug-centric repositioning research better than conventional drug-target pre-
diction approaches.  
Methods: We propose Bayesian Ranking Prediction of Drug-Target Interactions 
(BRDTI). The method is based on Bayesian Personalized Ranking matrix factorization 
(BPR) which has been shown to be an excellent approach for various preference learning 
tasks, however, it has not been used for DTI prediction previously.  In order to successfully 
deal with DTI challenges, we extended BPR by proposing: (i) the incorporation of target 
bias, (ii) a technique to handle new drugs and (iii) content alignment to take structural 
similarities of drugs and targets into account. 
Results: Evaluation on five benchmark datasets shows that BRDTI outperforms several 
state-of-the-art approaches in terms of per-drug nDCG and AUC. BRDTI results w.r.t. 
nDCG are 0.929, 0.953, 0.948, 0.897 and 0.690 for G-Protein Coupled Receptors (GPCR), 
Ion Channels (IC), Nuclear Receptors (NR), Enzymes (E) and Kinase (K) datasets respec-
tively. Additionally, BRDTI significantly outperformed other methods (BLM-NII, WNN-
GIP, NetLapRLS and CMF) w.r.t. nDCG in 17 out of 20 cases. Furthermore, BRDTI was 
also shown to be able to predict novel drug-target interactions not contained in the original 
datasets. The average recall at top-10 predicted targets for each drug was 0.762, 0.560, 
1.000 and 0.404 for GPCR, IC, NR, and E datasets respectively. 
Conclusions: Based on the evaluation, we can conclude that BRDTI is an appropriate 
choice for researchers looking for an in silico DTI prediction technique to be used in drug-
centric repositioning scenarios. BRDTI Software and supplementary materials are availa-
ble online at www.ksi.mff.cuni.cz/~peska/BRDTI. 
Keywords: Drug repositioning, drug-target interactions, machine learning, Bayesian 
Personalized Ranking 
1 Introduction  
Pharmaceutical science is an interdisciplinary research area comprising the findings from 
biology, chemistry, physics and informatics, with drug discovery being its main objective. 
One of the key steps in the process of drug discovery is to identify interactions between 
drugs and targets. Although the existence of interactions can be reliably confirmed by in 
vitro binding assays (e.g., [1–4]), such methods are still expensive in terms of both time 
and monetary value [5]. Therefore, in silico methods (i.e., virtual screening) can be applied 
to predict possible DTIs and  the most promising candidates can be verified experimentally 
[6–10] instead of performing an exhaustive in vitro search of novel interactions. Such ap-
proach is highly valuable in various scenarios such as developing drugs for rare diseases 
[11], repurposing off-patent drugs [12] or drugs failed in clinical trials [13] and can signif-
icantly reduce the cost of introducing novel drugs to the market [14]. 
There are two major classes of in silico prediction methods: docking simulations and ma-
chine learning methods. Docking simulations (e.g., [6–8,10,15,16]) leverage the 3D struc-
ture of targets in order to identify potential binding sites of the compounds. Docking sim-
ulations are biologically well-accepted but time consuming and require 3D structures of 
targets. Furthermore, some researchers report that standard molecular docking scoring 
functions may be replaced by machine learning based scoring functions with improved 
prediction results [17,18]. 
Machine learning methods in general leverage features based on the structure of drugs and 
targets (e.g., [9,19–21]), drugs’ side-effects [22], and the knowledge of already confirmed 
DTIs [23–32]. In particular, in case of Bipartite Local Models (BLM) [23] and its exten-
sions (e.g. [25], [32]), prediction of each DTI is based on the neighborhood of involved 
drug and target. Xia et al. [26] proposed a semi-supervised approach based on Laplacian 
regularized least square method (RLS) with kernels derived from known DTIs 
(NetLapRLS). Van Laarhoven et al. [27] proposed to use regularized least squares with 
Gaussian interaction profile kernel (GIP). The method was later improved by incorporating 
weighted nearest neighbors to be able to predict interactions also for new drugs and targets 
(WNN-GIP) [28].  
Another line of research focused on developing matrix factorization techniques for DTI 
prediction. The core idea is to map both drugs and targets into a shared low-dimensional 
latent feature space and to use this representation to calculate the probability of drug-target 
interactions. Matrix factorization techniques differ from one another especially in the op-
timization criteria, the choice of iterative optimization method and the exact inference of 
DTI probability. In particular, Gönen [29] proposed a kernelized Bayesian matrix factori-
zation (KBMF) method. KBMF utilizes drugs’ and targets’ similarity kernels 𝐊𝑑, 𝐊𝑡, de-
composes original DTI matrix as 𝐑 ≈ 𝐊𝒅
𝑻𝐀𝒅𝐀𝒕
𝑻𝐊𝑡 and thus considers drugs’ and targets’ 
similarity in DTI prediction. Zheng et al. [30] proposed the multiple similarities one-class 
matrix factorization (MSCMF) model with additive regularization based on multiple drug 
and target similarity matrices. Liu et al. [31] proposed neighborhood regularized logistic 
matrix factorization (NRLMF), with similar regularization terms as in MSCMF, however 
the similarity matrices were reduced via the nearest neighbor approach. 
Previously mentioned approaches focused on predicting the probability of interactions be-
tween all unknown drug-target pairs. Another alternative is to order unknown targets for 
each drug separately according to the expected interaction probability. We will further de-
note it as per-drug ranking. Although, for the first sight, the difference might appear to be 
minor, it affects both the evaluation protocol as well as the internal model of prediction 
methods, such as the optimization criteria of matrix factorization. Per-drug ranking ap-
proach is in accordance with drug-centric repurposing approach as described e.g. by Liu et 
al. [33]. Drug-centric repurposing approach is based on discovering new interactions for 
an existing drug d (especially for drugs demonstrated to be safe in Phase I clinical trials, 
but failed in subsequent Phase II and III trials). In such cases, only the ranking of interac-
tions with d are relevant. For similar tasks, several methods were proposed in the person-
alized ranking domain, such as BPR  [34] or RankALS [35].  
In this paper, we develop a DTI prediction model based on the Bayesian Personalized 
Ranking matrix factorization (BPR) [34].  BPR was designed to solve a ranking problem 
with positive-only information, which is a key challenge in the DTI prediction problem. 
However, other relevant circumstances of DTI prediction are not taken into account by 
BPR. Therefore, we extended BPR to comply with the DTI prediction setting. In particular, 
the proposed BRDTI is able to handle the case of new drugs and takes chemical and genetic 
similarities of drugs and targets and target bias into account. Note that, although we focus 
on the drug-centric approach, after appropriate modifications BRDTI can be utilized for 
disease-centric repurposing scenarios as well. To the best of our knowledge, this is the first 
approach to utilize a matrix factorization technique from the personalized ranking domain 
for DTI prediction and to evaluate the predicted DTIs with respect to the drug-centric re-
purposing scenario. 
The main contributions of this paper are: 
- BRDTI method for prediction of DTIs. 
- We evaluate predictions both in terms of AUC and per-drug normalized discounted 
cumulative gain (nDCG). As we will discuss, the per-drug nDCG reflects the re-
quirements of drug-centric approach for drug repositioning better than the widely-
used AUC. 
- Comparative evaluation of BRDTI and four state-of-the-art methods with respect 
to this scenario. 
- Datasets of recently confirmed DTIs, extending the ones published by Yamanishi 
et al. [24]. 
2 Materials and Methods 
2.1 Materials 
To evaluate the proposed methods, we use five benchmark datasets: G-Protein Coupled 
Receptors (GPCR), Ion Channels (IC), Nuclear Receptors (NR) and Enzymes (E) datasets 
originally published by Yamanishi et al. [24] and the Kinase (K) dataset [36]. Each of the 
first four datasets contains a binary interaction matrix between drugs and targets, in which 
each entry indicates whether the interaction between the corresponding drug and target is 
known or not. In contrast, Kinase contains continuous values of binding affinity for drug–
target pairs. In order to produce a binary interaction matrix, we used the same cutoff thresh-
old as Pahikkala et al. [37]. Drug-to-drug similarities were computed based on the chemical 
structure of the compound via the SIMCOMP algorithm (GPCR, IC, NR and E datasets) 
or via the 2D Tanimoto coefficients (Kinase dataset). Target-to-target similarities were 
computed as the normalized Smith-Waterman score of amino acid sequences of target pro-
teins. 
To verify the proposed novel DTIs predicted by the proposed methods, we also constructed 
the dataset of recently confirmed DTIs on the same sets of drugs and targets as in the orig-
inal four dataset by Yamanishi et al. [24].  The dataset was constructed by collecting the 
drugs’ and targets’ profiles from up-to-date versions of KEGG [38], DrugBank [39] and 
Matador [40] databases and parsing the verified DTIs. This dataset is available in supple-
mentary materials. Table 1 contains some basic statistics of both original and extended 
datasets. 
2.2 Basic Notation and Problem Formalization 
In this paper, we denote the set of drugs as 𝐷 = {𝑑1, … , 𝑑𝑛} and the set of targets as 𝑇 =
{𝑡1, … , 𝑡𝑚}, where 𝑛 and 𝑚 are the number of drugs and targets respectively. The 𝑛 × 𝑚 
matrix 𝐑 represents known drug-target interactions. 𝐑 is a binary matrix with entries 𝑟𝑖,𝑗 =
1 denoting that a drug 𝑑𝑖 has been experimentally verified to interact with a target 𝑡𝑗, oth-
erwise: 𝑟𝑖,𝑗 = 0. The matrix 𝐒
𝐷 ∈ ℝ𝑛×𝑛 represents drug similarity. Each element 𝑠𝑖,𝑘
𝐷  con-
tains the similarity between drugs 𝑑𝑖 and 𝑑𝑘. Analogically, the matrix 𝐒
𝑇 ∈ ℝ𝑚×𝑚 repre-
sents target similarity. 
We further define sets of novel drugs 𝐷𝑁 and targets 𝑇𝑁 as the drugs (targets) without any 
known interaction: 𝐷𝑁 = {𝑑𝑖 ∈ 𝐷; ∑ 𝑟𝑖,𝑗
𝑚
𝑗=1 = 0}, 𝑇
𝑁 = {𝑡𝑗 ∈ 𝑇; ∑ 𝑟𝑖,𝑗
𝑛
𝑖=1 = 0}. 
Matrix factorization methods aim to map both drugs and targets into a shared latent space, 
where 𝑓 denotes its dimension (number of latent factors), 𝛍𝑖 ∈ ℝ
𝑓denotes the latent factors 
of drug 𝑑𝑖 and 𝛎𝑗 ∈ ℝ
𝑓denotes the latent factors of target 𝑡𝑗. We further define 𝐔 ∈ ℝ
𝑛×𝑓as 
the matrix of all drugs’ latent factors and 𝐕 ∈ ℝ𝑚×𝑓 as the matrix of all targets’ latent 
factors. The predicted probability of interaction ?̂?𝑖,𝑗 between drug 𝑑𝑖 and target 𝑡𝑗 is defined 
Table 1. Basic statistics of the DTI datasets used in evaluation. 
Dataset: GPCR Ion Channel NR Enzymes Kinase  
Drugs 223 210 54 445 1421 
Targets 95 204 26 664 156 
Positive interactions 635 1476 90 2926 2798 
Sparsity 97.0% 96.6% 93.6% 99.0% 98.7% 
Recently confirmed interactions 618 1367 27 502 - 
  
 
 
as the dot product of its latent factors ?̂?𝑖,𝑗 ≔ 𝛍𝑖 × 𝛎𝑗
𝑇, thus the matrix of predicted DTIs ?̂? 
can be inferred as ?̂? = 𝐔𝐕𝑇 . We further define the per-drug training set as the set of triples 
𝐷𝑠 ⊂ 𝐷 × 𝑇 × 𝑇, 𝐷𝑠 ≔ {(𝑑𝑖 , 𝑡𝑗 , 𝑡𝑘): 𝑟𝑖,𝑗 = 1 ∧ 𝑟𝑖,𝑘 = 0}.  
We consider the problem of DTI prediction from the perspective of drug-centric reposi-
tioning scenario. Thus, the objective for the DTI prediction method is as follows: 
 For arbitrary fixed drug 𝑑 ∈ 𝐷, provide total ordering of all considered targets <𝑑 
such that top-ranked targets should interact with the drug 𝑑 with the highest proba-
bility.  
2.3 Bayesian Personalized Ranking Matrix Factorization 
In this section we describe the BPR method [34] in the context of DTI prediction. BPR 
aims to optimize per-drug ranking by reducing it to pairwise classification of interacting 
and non-interacting targets. Optimization criterion is based on correctness of the pairwise 
classification and maximized via stochastic gradient descend with bootstrap sampling of 
training points.  
More specifically, the Bayesian formulation of finding correct per-drug ranking of all tar-
gets 𝑡 ∈ 𝑇 is to maximize posterior probability:  
𝑝(Θ | >𝑑) ∝ 𝑝(>𝑑|Θ) 𝑝(Θ) 
where Θ represents parameters of matrix factorization. The >𝑑 is desired, but latent order-
ing, specific for the drug 𝑑. BPR method further assumes independency of drugs on each 
other, independency of ordering pairs of targets on any other pairs, totality and antisym-
metry of the ordering. Hence, the drug-specific likelihood function 𝑝(Θ | >𝑑) can be com-
bined for all drugs as follows: 
∏ 𝑝(>𝑑|Θ)
𝑑∈𝐷
=  ∏ 𝑝(𝑡𝑗 >𝑑
(𝑑,𝑡𝑗,𝑡𝑘)∈𝐷𝑠
𝑡𝑘|Θ) 
The individual probability that drug 𝑑 interacts with target 𝑡𝑗 rather than with 𝑡𝑘 is defined 
as follows: 
𝑝(𝑡𝑗 >𝑑 𝑡𝑘|Θ) ≔  𝜎(?̂?𝑑,𝑗,𝑘(Θ)) 
where 𝜎 is the logistic sigmoid function 𝜎(𝑥) ≔ 1/(1 + 𝑒−𝑥) and ?̂?𝑑,𝑗,𝑘(Θ) is a real-valued 
evaluation function of the underlying model, capturing the relationship between drug 𝑑, 
target 𝑡𝑗 and target 𝑡𝑘. For matrix factorization, the natural definition of ?̂?𝑑,𝑗,𝑘 is to substract 
predicted ratings of known and unknown interaction: ?̂?𝑑,𝑗,𝑘 ≔ ?̂?𝑑,𝑗 − ?̂?𝑑,𝑘 and model pa-
rameters Θ are the latent factors of drugs and targets: Θ = (𝐔, 𝐕). BPR method further 
assumes the prior density of model parameters to be of normal distribution with zero mean 
𝑝(Θ)~𝑁(0, 𝜆𝜃𝐼), where 𝜆𝜃 is a model specific regularization parameter. Thus the optimi-
zation criterion BPR-OPT can be derived as follows: 
BPR-OPT ≔ ln 𝑝(Θ | >𝑑)                                                                   
 = ln 𝑝(>𝑑|Θ) 𝑝(Θ)                                                          
 
= ln ∏ 𝑝(𝑡𝑗 >𝑑
(𝑑,𝑡𝑗,𝑡𝑘)∈𝐷𝑠
𝑡𝑘|Θ)𝑝(Θ)                               
= ∑ ln  𝜎 (?̂?𝑑,𝑗,𝑘(Θ)) + ln  𝑝(Θ)                       
(𝑑,𝑡𝑗,𝑡𝑘)∈𝐷𝑠
= ∑ ln  𝜎 (?̂?𝑑,𝑗,𝑘(Θ)) − 𝜆𝜃‖Θ‖
2    
(𝑑,𝑡𝑗,𝑡𝑘)∈𝐷𝑠
                   
= ∑ ln  𝜎(?̂?𝑖,𝑗 − ?̂?𝑖,𝑘) − 𝜆𝑅(‖𝐔‖
2 + ‖𝐕‖2)    
(𝑑𝑖,𝑡𝑗,𝑡𝑘)∈𝐷𝑠
 
2.4 Modifying BPR for DTI prediction 
Although there is a certain level of similarity between DTI prediction problem and the 
personalized ranking in preference learning, these problems differ in several important as-
pects. First, some well-founded metrics of drugs’ and targets’ similarity were proposed 
(e.g., [24,36]) and the underlined latent space model should reflect those similarities. Fur-
thermore, DTI prediction methods should be able to provide predictions also for drugs and 
targets without any known interactions. The rest of this section provides insight on how we 
extended BPR in order to comply with these requirements. 
2.4.1  Content Alignment for BPR  
  We note that drugs and targets are not independent and we can define similarity matrices 
𝐒𝐷, 𝐒𝑇 describing relations between drugs and targets respectively. The aim of content 
alignment is to reflect the aforementioned similarities during the matrix decomposition 
process. Therefore, we extend the BPR optimization criterion by an additive regularization 
based on the similarity of objects (drugs and targets) and its latent factors. Using the work 
of Nguyen and Zhu [41], we implemented a regularization based on the squared norm of 
the latent factors distance. The regularization was applied on both the drug, the interacting 
target and the non-interacting target of training set entries (𝑑𝑖 , 𝑡𝑗 , 𝑡𝑘) ∈ 𝐷𝑠. The optimiza-
tion term CA for the training set entry (𝑑𝑖 , 𝑡𝑗 , 𝑡𝑘) ∈ 𝐷𝑠 is as follows: 
CA = 𝜆𝐶 (∑ 𝐒𝑖,𝑖̅
𝐷
𝑛
𝑖=̅1
‖𝛍𝑖 − 𝛍𝑖̅‖
2 + ∑ 𝐒𝑗,?̅?
𝑇
𝑚
?̅?=1
‖𝛎𝑗 − 𝛎?̅?‖
2
+ 𝐒𝑘,?̅?
𝑇 ‖𝛎𝑘 − 𝛎?̅?‖
2
) 
However, our intention is to impose the latent factors’ similarity only on highly similar 
drugs or targets as the large volume of objects with low similarity could significantly bias 
the results. In order to achieve this, the similarity matrices 𝐒𝐷 and 𝐒𝑇 were reduced to con-
tain only the top-k most similar neighbors to each drug and target. In order to keep the 
model simple, we empirically define 𝑘 = 5. This approach is in line with the one used by 
Liu et al. [31] and in addition to the performance improvements, it also increases compu-
tational efficiency.  
2.4.2 Adding Target Bias to BPR 
In preference learning, much of the observed variation can be attributed to the latent effects 
associated solely with the objects, independent of their interactions [42]. Such effects may 
be captured by bias terms in the prediction model. In DTI datasets some targets have higher 
number of interactions than others, thus their probability to interact with a drug is higher 
in general. To cope with this effect, we incorporated target bias into the optimization cri-
teria and DTI prediction. Denoting the bias of target 𝑡𝑗 as 𝑏𝑗  and the vector of all biases as 
𝒃, the biased optimization criteria BPR-OPTbias and biased DTI prediction ?̂?𝑖,𝑗,𝒃 can be de-
fined as follows. 
?̂?𝑖,𝑗,𝒃 = 𝑏𝑗 + 𝛍𝑖 × 𝛎𝑗
𝑇                                                                                        
BPR-OPTbias = ∑ ln  𝜎(?̂?𝑖,𝑗,𝒃 − ?̂?𝑖,𝑘,𝒃) − 𝜆𝑅(‖𝐔‖
2 + ‖𝐕‖2 + ‖𝒃‖2)
(𝑑𝑖,𝑡𝑗,𝑡𝑘)∈𝐷𝑠
                    
                         = ∑ ln  𝜎 (𝑏𝑗 + ?̂?𝑖,𝑗 − (𝑏𝑘 + ?̂?𝑖,𝑘)) − 𝜆𝑅(‖𝐔‖
2 + ‖𝐕‖2 + ‖𝒃‖2)
(𝑑𝑖,𝑡𝑗,𝑡𝑘)∈𝐷𝑠
 
 
2.4.3 DTI Prediction for Novel Drugs and Targets  
In case of the novel drugs 𝑑 ∈ 𝐷𝑁  and targets 𝑡 ∈ 𝑇𝑁 with no known interaction, BPR 
method can only learn their latent factors through negative examples (unknown DTIs). 
However, as those DTIs are not confirmed to be negative (in fact, some of them are actually 
confirmed DTIs, hidden during the training phase), learning from negative-only infor-
mation inevitably corrupts the model. In order to overcome this problem, we use neighbor-
hood-based approach for novel drugs and targets. After the training phase, latent factors 
and biases of each novel drug 𝑑𝑖 ∈ 𝐷
𝑁 and novel target 𝑡𝑗 ∈ 𝑇
𝑁 are approximated by the 
linear combination of its neighbors’ latent factors: 
𝛍𝑖 =
∑ 𝐒𝑖,𝑖̅
𝐷 𝛍𝑖̅𝑖≠̅𝑖
∑ 𝐒𝑖,𝑖̅
𝐷
𝑖≠̅𝑖
;              𝛎𝑗 =
∑ 𝐒𝑗,?̅?
𝑇 𝛎?̅??̅?≠𝑗
∑ 𝐒𝑗,?̅?
𝑇
?̅?≠𝑗
;              𝑏𝑗 =
∑ 𝐒𝑗,?̅?
𝑇 𝑏?̅??̅?≠𝑗
∑ 𝐒𝑗,?̅?
𝑇
?̅?≠𝑗
 
2.4.4 BRDTI Method 
To sum up, we propose Bayesian Personalized Ranking Prediction of Drug-Target Inter-
actions (BRDTI) method, which is assembled as follows. The original BPR method’s reg-
ularization is extended with content alignment CA, biased DTI prediction formula ?̂?𝑖,𝑗,𝒃 is 
used and in case of novel drug or target, neighborhood-based approximation is applied. 
The final BRDTI optimization criterion is: 
BRDTI-OPT = ∑ ln  𝜎 (𝑏𝑗 + ?̂?𝑖,𝑗 − (𝑏𝑘 + ?̂?𝑖,𝑘))
(𝑑𝑖,𝑡𝑗,𝑡𝑘)∈𝐷𝑠
 −𝜆𝑅(‖𝐔‖
2 + ‖𝐕‖2 + ‖𝒃‖2 + CA)
 
Bootstrapped stochastic gradient ascend is used to maximize the BRDTI-OPT criterion. 
Update rules for each parameter are as follows: 
 
𝑏𝑗 = 𝑏𝑗 + 𝜂(𝑥 − 𝜆𝑅𝑏𝑗)                                                                                
𝑏𝑘 = 𝑏𝑘 + 𝜂(−𝑥 − 𝜆𝑅𝑏𝑘)                                                                            
𝛍𝑖 = 𝛍𝑖 + 𝜂 (𝑥 ∙ (𝛎𝑗 − 𝛎𝑘) − 𝜆𝑅𝛍𝑖 − 𝜆𝑅𝜆𝐶 (𝐒𝑖
𝐷𝛍𝑖 − ∑ 𝐒𝑖,𝑖̅
𝐷 𝛍𝑖̅
𝑛
𝑖=̅1
)) 
𝛎𝑗 = 𝛎𝑗 + 𝜂 (𝑥 ∙ 𝛍𝑖 − 𝜆𝑅𝛎𝑗 − 𝜆𝑅𝜆𝐶 (𝐒𝑗
𝑇𝛎𝑗 − ∑ 𝐒𝑗,?̅?
𝑇 𝛎?̅?
𝑚
?̅?=1
))               
𝛎𝑘 = 𝛎𝑘 + 𝜂 (𝑥 ∙ (−𝛍𝑖) − 𝜆𝑅𝛎𝑘 − 𝜆𝑅𝜆𝐶 (𝐒𝑘
𝑇𝛎𝑘 − ∑ 𝐒𝑘,?̅?
𝑇 𝛎?̅?
𝑚
?̅?=1
))     
 
 
where 𝑥 = 𝜎 (𝑏𝑗 + ?̂?𝑖,𝑗 − (𝑏𝑘 + ?̂?𝑖,𝑘)) and hyperparameters 𝜂, 𝜆𝑅 and 𝜆𝐶 are learning rate, 
general regularization and content alignment regularization respectively. Algorithm 1 con-
tains pseudocode of the proposed method. 
FUNCTION OPTIMIZE_BRDTI 
Input:    𝑓, 𝜂, 𝜆𝑅, 𝜆𝐶, max_iterations, k, 𝐑, 𝐒
𝐷, 𝐒𝑇 
Output: ?̂? 
1: Initialize 𝐔, 𝐕, 𝒃 
2: Alter 𝐒𝐷, 𝐒𝑇 to contain only top-k closest neighbors for each item 
3: Repeat: 
4:    Foreach (𝑑𝑖 , 𝑡𝑗):  𝑟𝑖,𝑗 = 1: 
5:        Draw random  𝑡𝑘:  𝑟𝑖,𝑘 = 0 
6:        Update 𝑏𝑗 , 𝑏𝑘, 𝛍𝑖, 𝛎𝑗 , 𝛎𝑘 
7:    end foreach 
8: Until max_iterations is reached    
Algorithm 1. Optimization of BRDTI method 
2.5 Normalized Discounted Cumulative Gain 
As we consider DTI prediction to be a per-drug ranking problem, we evaluate ranked lists 
for each drug separately and use normalized discounted cumulative gain (nDCG) as eval-
uation metric, which was shown to be the best graded relevance ranking metric with respect 
to the stability and sensitivity [43]. For the ranked list p DCG is calculated as follows: 
𝐷𝐶𝐺(𝑝) = ∑
𝑟𝑖
log2(𝑖 + 1)
|𝑝|
𝑖=1
  
where  𝑟𝑖   denotes the relevance of its i-th element. In our case  𝑟𝑖 = 1 or   𝑟𝑖 = 0  depending 
on whether the interaction corresponding to this element of the list is contained in the test 
set. The normalization is done by dividing the DCG by the DCG of the ideal ordering of 
the same size. Thus 𝑛𝐷𝐶𝐺 ∈ [0,1]; higher values indicate better performance. 
There are several advantages of using nDCG as evaluation metric for DTI. 
1) Each position in the ranked list is associated with a gradually decreasing weight, 
reflecting the potential impact of relevant object placed on the respective posi-
tion. This reflects well the drug repositioning scenario, where confirmation of 
each further candidate DTI is both temporally and monetarily expensive. 
2) nDCG may  use graded relevance characteristics, allowing to distinguish DTIs 
with higher potential impact from the others. 
3) nDCG can be naturally truncated to consider only top-k objects and thus reflect 
the scenario, where exhaustive validation of all proposed DTIs is not possible 
and we can only verify several predicted DTIs. 
3 Evaluation and Results 
Similarly as in previous studies (e.g., [30]), the performance of BRDTI method was eval-
uated via five times repeated 10-fold cross-validation (5x10-fold CV). In each of the five 
repetitions, we randomly assign known DTIs to one out of ten splits. Then, we run 10-fold 
CV. In each of the ten iterations of 10-fold CV, a different split is used as test set, while 
the remaining splits are used as training set (matrix R). We adopted normalized discounted 
cumulative gain (nDCG) as an evaluation metric and evaluate the results in a per-drug 
fashion. We report the average nDCG values over all drugs and CV runs and denote it as 
per-drug nDCG. In order to remain comparable with previous studies, we also provide 
results in terms of AUC.  
The proposed BRDTI method was compared with four state of the art approaches: BLM-
NII [25], WNN-GIP [28], NetLapRLS [26] and CMF [30]. Grid-search was used to tune 
methods’ hyperparameters, details can be found in supplementary materials.  
3.1 Results 
Table 2. Per-drug nDCG for unknown DTIs prediction. The best results and the results without 
a significant difference to it (𝑝 < 0.05 according to paired t-test) are in bold.  
   Per-drug nDCG BLM-NII WNN-GIP NetLapRLS CMF BRDTI 
  GPCR 0.887  0.890  0.917  0.910  0.929  
  Ion Channels 0.928  0.895  0.930  0.954  0.953  
  Nuclear Receptors 0.919  0.920  0.941  0.910  0.948  
  Enzymes 0.872  0.860  0.871  0.873  0.897  
  Kinase 0.470  0.289  0.670  0.694  0.690  
Table 3. AUC for unknown DTIs prediction. The best results and the results without a significant 
difference to it (𝑝 < 0.05 according to paired t-test) are in bold.  
AUC BLM-NII WNN-GIP NetLapRLS CMF BRDTI 
  GPCR 0.943  0.931  0.799  0.938  0.955  
  Ion Channels 0.980  0.955  0.864  0.981  0.982  
  Nuclear Receptors 0.902  0.894  0.847  0.846  0.923  
  Enzymes 0.971  0.960  0.960  0.960  0.981  
  Kinase 0.850  0.657  0.764  0.937  0.914  
 
 
Table 2 shows results in terms of nDCG. BRDTI method achieved the best results on 
GPCR, Nuclear Receptors and Enzymes datasets and second best (without significant dif-
ference) on Ion Channel and Kinase datasets. In pairwise comparison (paired t-test, 𝑝 <
0.05), BRDTI significantly outperformed its competitors in 17 out of 20 cases w.r.t. nDCG. 
Table 3 shows the results in terms of AUC. BRDTI achieved the best results w.r.t. AUC 
except on Kinase dataset, where it ended second. BRDTI significantly outperformed its 
competitors in 18 out of 20 cases w.r.t. AUC.  The performance of the methods is further 
illustrated in Figure 1 by ROC curves on the GPCR dataset. Other datasets exhibited sim-
ilar ROC curves and thus we omit them. We can conclude that BRDTI can be successfully 
applied to predict DTIs for existing drugs.  
Table 4 shows the results of nDCG for several variants of the BPR algorithm. The evalu-
ated variants are:  
- Original BPR algorithm without further modifications (BPR) 
- BPR with neighborhood approximation for new drugs and targets (BPR-NA) 
- BPR with content alignment (BPR-CA) 
- BPR with neighborhood approximation and content alignment performed on full 
𝐒𝐷and 𝐒𝑇 matrices (BPR-NA-CA-F) 
- Final BRDTI method 
 
Figure 1: ROC curves of the evaluated DTI prediction methods on GPCR dataset. 
Described variants represent design choices made during BRDTI assembling and the re-
sults support our decisions as BRDTI significantly outperformed the other approaches. 
3.2 Predicting Recently Confirmed DTI 
In this section, we illustrate that BRDTI not only achieves high accuracy in terms of nDCG 
and AUC, but its predictions are biologically feasible as well. Note that the drug–target 
interactions contained in the Enzyme, Ion Channel, GPCR and NR datasets were extracted 
several years ago and they have been kept unchanged to allow comparison between DTI 
prediction methods. Further interactions between the same drugs and targets have been 
confirmed recently (i.e., after the publication of the original datasets). Our intention is to 
demonstrate that BRDTI is a viable method for disclosing  unknown interactions as it is 
capable of predicting the aforementioned recently confirmed interactions by learning from 
those interactions that were known previously (i.e., from interactions contained in the orig-
inal datasets). Therefore, we trained BRDTI and its competitors using all the interactions 
of the original datasets,  predict per-drug ranking of all unknown drug-target pairs and 
compare the predictions with the list of recently confirmed DTIs. Figure 2 illustrates the 
approach. 
We validated predicted interactions in up-to-date versions of KEGG, DrugBank and Mat-
ador databases. Overall, 2514 recently confirmed DTI were found. However, for a substan-
tial portion of drugs (61%), there were no recently confirmed interactions and thus they 
were excluded. Table 5 depicts the results w.r.t. top-10 considered targets for each drug. 
 
Figure 2: Evaluation workflow using recently confirmed DTIs. 
BRDTI performs the best, closely followed by NetLapRLS. Performance of CMF is con-
siderably lower compared to the results in the original datasets.  
3.3 Drug Repurposing Based on the DTI Predictions 
Next, we will illustrate that the predictions of BRDTI may contribute to promising thera-
peutic hypotheses. As an example, we point out that we predicted the validated interaction 
between Pentazocine (D00498) and Opioid receptor kappa1 (hsa4986). The receptor is dis-
tributed in various parts of the brain, and Pentazocine is indeed used as an analgetic. 
For Parkinson disease, recent studies proposed the examination of glutamate metabotropic 
receptor 4 (GRM4, hsa2914) positive allosteric modulators as supplementary treatment 
[44–47]. While Eglumetad (D03966) is known to have antianxiety activity and to be a 
glutamate metabotropic receptor 2 (GRM2, hsa2912) agonist, we predicted Eglumetad to 
interact with GRM4 as well. As Parkinson patients often have anxiety, it would be inter-
esting to examine Eglumetad as a supplementary therapy in Parkinson patients with anxi-
ety. 
Finally, we point out that Lipoyltransferase 1 gene (LIPT1) defects cause Leigh disease 
[48] and, in case of severe defects, fatal lactic acidosis [49,50]. We hypothesize that in 
some cases of LIPT mutations, an agonist could help to increase enzymatic activity. We 
predicted Biotin (D00029) to interact with LIPT1 (hsa51601). Biotin is transported across 
Table 4.  Per-drug nDCG for unknown DTIs prediction – comparing variants of BPR with 
BRDTI. The best results and the results without a significant difference to it (𝑝 < 0.05 according 
to paired t-test) are in bold. 
Per-drug nDCG BPR BPR-NA BPR-CA BPR-NA-CA-F BRDTI 
  GPCR 0.865  0.909  0.887  0.866  0.929  
  Ion Channels 0.915  0.942  0.934  0.929  0.953  
  Nuclear Receptors 0.906  0.944  0.920  0.928  0.948  
  Enzymes 0.824  0.887  0.838  0.816  0.897  
Table 5.  Prediction of novel DTIs – top-10 predictions for each drug. In each column, the val-
ues represent nDCG and recall@top-10 respectively. The best results and the results without a 
significant difference to it (𝑝 < 0.05 according to paired t-test) are in bold.  
nDCG / 
recall@top-10 
BLM-NII WNN-GIP NetLapRLS CMF BRDTI 
  GPCR 0.704 / 0.740 0.640 / 0.635 0.738 / 0.730 0.635 / 0.677 0.765 / 0.762 
  Ion Channels 0.479 / 0.486 0.408 / 0.361 0.552 / 0.512 0.356 / 0.366 0.566 / 0.560 
  Nuclear Receptors 0.744 / 0.962 0.613 / 0.808 0.807 / 1.000 0.796 / 0.992 0.826 / 1.000 
  Enzymes 0.328 / 0.351 0.250 / 0.259 0.354 / 0.382 0.030 / 0.066 0.356 / 0.404 
 
 
 
the blood-brain barrier and it was proposed as a treatment of multiple sclerosis previously 
[51]. Based on our aforementioned prediction, it would be interesting to examine Biotin as 
a potential therapy for LIPT1 mutations as well. 
4 Discussion 
This paper considers the problem of DTI predictions for drug-centric repositioning ap-
proach. We pointed out that such an approach may benefit from carefully optimized rank-
ing of possible targets for a specific drug and presented a novel DTI prediction method, 
BRDTI. The novelty of the method comes from applying per-drug ranking optimization 
criteria, while projecting drugs and targets to the shared latent space. Furthermore, content 
alignment of latent vectors is applied for similar drugs and targets, unknown drugs and 
targets are blended via its neighbors and target bias is applied. BRDTI method was exten-
sively evaluated over five datasets together with four state-of-the-art approaches. Overall, 
BRDTI performed the best with respect to per-drug nDCG as well as AUC. We also eval-
uated BRDTI predictions on recently confirmed interactions. Also in this case, BRDTI 
method achieved very good results and confirmed to be suitable for future predictions. Note 
that substantial decrease in performance of all methods in Enzymes dataset can be ex-
plained by the ratio between recently confirmed DTIs and all unknown interactions in the 
original dataset. Whereas for Enzymes dataset, there were only 502 recently confirmed 
DTIs (0.17% of all unknown DTIs), the ratio was an order of magnitude higher for the 
other three datasets (3.0% for GPCR, 3.3% for IC and 2.1% for NR). Generally, there is 
relatively large overlap in the method’s ranked lists. However, in several occasions, BRDTI 
was the only method able to predict any confirmed DTIs for a specific drug, e.g., connec-
tion of Trimethoprim (D00145) - Thymidylate synthetase (hsa:7298) and Chlorothiazide 
(D00519) - Renin (hsa:5972). 
However, results of recently confirmed DTI prediction also illustrate that there is still room 
for improvement as some of the new interactions were neglected by all evaluated methods. 
This can be illustrated on the example of Haldol (D00136), for which 10 new interactions 
are known, however none of the evaluated method listed any of these interactions into the 
top-10 predictions. As there were neither strong similarities between original and new tar-
gets, nor substantial collaborative information through similar drugs, it is important to de-
fine and incorporate further concepts of similarity into the prediction models (e.g., [52,53]).  
The full list of DTIs predicted by BRDTI method can be found in supplementary materials. 
Also, note that BRDTI source codes can be easily modified to run BRDTI on further da-
tasets, see also the instructions in the supplementary materials. 
Success of BRDTI method encourages us to test further ranking methods, e.g., RankALS 
[35] for DTI prediction task. Furthermore, it would be interesting to develop DTI predic-
tion techniques that are able to take specific conditions (temperature, cell type or subtype, 
presence or absence of a disease, etc.) into account and make DTI predictions for those 
conditions. For example, Wenzel et al. [54] reported that their bimetallic cytotoxic com-
plexes were shown to be easily taken up by cancer cells at 37 °C, whereas experiments at 
4 °C showed no uptake. Incorporation of the aforementioned conditions into DTI predic-
tion methods, in order to allow for more specific predictions, is left for future work.  
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